Ceramide generation by two distinct pathways in tumor necrosis factor α-induced cell death  by Dbaibo, Ghassan S et al.
Ceramide generation by two distinct pathways in tumor necrosis factor
K-induced cell death
Ghassan S. Dbaiboa;b;*, Wissal El-Assaada;b, Armand Krikorianb, Bin Liud, Karim Diabb,
Nadine Z. Idrissb, Marwan El-Sabbanc, Timothy A. Driscolle, David K. Perryf ,
Yusuf A. Hannunf
aDepartment of Pediatrics, American University of Beirut, Beirut, Lebanon
bDepartment of Biochemistry, American University of Beirut, Beirut, Lebanon
cDepartment of Human Morphology, American University of Beirut, Beirut, Lebanon
dNeuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute for Environmental Health Sciences,
Research Triangle Park, NC 27709, USA
eDepartment of Pediatrics, Duke University, Durham, NC 27710, USA
f Department of Biochemistry and Molecular Biology, Medical College of South Carolina, Charleston, SC 29425, USA
Received 20 May 2001; revised 16 June 2001; accepted 18 June 2001
First published online 23 July 2001
Edited by Guido Tettamanti
Abstract Ceramide accumulation in the cell can occur from
either hydrolysis of sphingomyelin or by de novo synthesis. In this
study, we found that blocking de novo ceramide synthesis
significantly inhibits ceramide accumulation and subsequent cell
death in response to tumor necrosis factor K. When cells were
pre-treated with glutathione, a proposed cellular regulator of
neutral sphingomyelinase, inhibition of ceramide accumulation
at early time points was achieved with attenuation of cell death.
Inhibition of both pathways achieved near-complete inhibition
of ceramide accumulation and cell death indicating that both
pathways of ceramide generation are stimulated. This illus-
trates the complexity of ceramide generation in cytokine
action. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Ceramide has been proposed as a coordinator of the re-
sponse to stress including the propagation of the apoptotic
signal produced not only by death receptors, but also by sen-
sors of genotoxic stress such as p53 [1,2]. Generation of cer-
amide from the hydrolysis of membrane sphingomyelin by the
action of sphingomyelinases is a primary mechanism for rap-
idly increasing ceramide levels in the cell. Several sphingomye-
linases have been identi¢ed, but not all of them have been
fully characterized [3]. The neutral magnesium-dependent
sphingomyelinase (N-SMase) has been linked to apoptosis
mediated by tumor necrosis factor K (TNFK), Fas, serum
starvation, and some chemotherapeutic agents [4,5]. Recently,
glutathione (GSH) was shown to inhibit the activation of
N-SMase both in partially puri¢ed preparations and in cells
treated with TNFK [5,6]. GSH is the most abundant thiol-
containing cellular antioxidant and it is rapidly depleted in
response to various apoptotic stimuli, especially those result-
ing in the generation of reactive oxygen intermediates (ROI)
[7,8]. This, along with its demonstrated e¡ects on N-SMase,
raised the possibility that N-SMase may be speci¢cally
coupled to the oxidative stress response via GSH. Increased
acidic sphingomyelinase (A-SMase) activity has also been
shown in response to Q-irradiation, Fas, and TNFK [9^11].
The role of other sphingomyelinases has not yet been deter-
mined.
Ceramide can also be generated by de novo synthesis via
condensation of L-serine and palmitoyl-CoA followed by re-
duction of the resulting ketosphinganine to sphinganine.
N-acylation of sphinganine by ceramide synthase produces
dihydroceramide, which is then desaturated between carbons
four and ¢ve to give ceramide. In addition, cellular sphingo-
sine can be N-acylated by ceramide synthase to give ceramide.
De novo synthesis of ceramide has been implicated in ceram-
ide accumulation in response to retinoic acid [12], and activa-
tion of ceramide synthase has been suggested as the mecha-
nism for the elevation of ceramide and induction of
apoptosis in response to the chemotherapeutic agent dauno-
rubicin [13].
The role of ceramide in apoptosis, especially that induced
by TNFK, has been the subject of some controversy [14,15]. In
this study, we show that TNFK treatment of either MCF7
breast carcinoma or L929 murine ¢brosarcoma cells results
in the activation of two pathways of ceramide generation:
one that is inhibitable by GSH (and is probably mediated
by N-SMase), and the second is dependent on de novo syn-
thesis of ceramide and is inhibitable by fumonisin B1 (FB1).
We show that by blocking both pathways, signi¢cant delay of
cell death is achieved, suggesting an important role for the
accumulated ceramide in the propagation of TNFK-induced
apoptosis.
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2. Materials and methods
2.1. Cell culture and viability assays
The TNFK-sensitive MCF7 (a kind gift from Dr. Vishva Dixit,
Genentech, south San Francisco, CA, USA) and L929 (American
Type Culture Collection, Rockville, USA) cell lines were grown in
RPMI1640 and Dulbecco’s modi¢ed Eagle’s medium, respectively.
Cell viability was determined either by the ability to exclude trypan
blue or the ability to cleave the tetrazolium salt WST-1 to formazan
by mitochondrial dehydrogenases in viable cells and by following the
manufacturer’s procedure (Boehringer Mannheim, Germany). MCF7
cells were treated with TNFK at 1 nM, whereas L929 cells were
treated with TNFK at 0.1 nM, unless indicated otherwise. Cells
were treated with GSH at 10 mM unless indicated otherwise.
Apoptotic cells were identi¢ed as follows: L929 cells were seeded at
5U104 cells on 10-mm cover slips and rested overnight. Following
treatment, the cells were then stained in a (0.5 Wg/ml) solution
Hoechst 33342 (Molecular Probes) for 10 min, then ¢xed with 4%
formaldehyde. The stained nuclei were visualized by £uorescence mi-
croscopy using a FITC range ¢lter on a Zeiss confocal microscope
¢tted with a Nikon 6006 camera. Apoptotic cells were de¢ned by the
condensation of nuclear chromatin, its fragmentation, or its margin-
ation to the nuclear membrane. The percentage of apoptotic cells was
determined after counting at least 200 cells. Experiments were done in
duplicate at least twice.
2.2,. Ceramide measurement
Cells were seeded at 1U106 cells/ml in a 100-mm Petri dish in 5 ml
volume, rested overnight, then treated with TNFK. Lipids were col-
lected as described [16]. Ceramide was measured using a modi¢ed
diacylglycerol kinase assay using external ceramide standards as de-
scribed previously, and expressed as a ratio of ceramide over lipid
phosphate [17].
For assessing de novo ceramide synthesis, labeling with palmitate
was utilized. MCF7 cells were seeded at 5U105 cells/well in 6-well
culture plates in RPMI with 10% fetal bovine serum (3.5 ml of me-
dium/well). Cells were allowed to grow for 24 h and were then treated
with 3 WCi/well of [9,10-3H(N)]palmitate (New England Nuclear) and
immediately treated with vehicle control, TNFK or FB1. Lipids were
extracted from harvested cells and palmitate incorporation into newly
synthesized ceramide was measured as described [18]. Results are ex-
pressed as cpm of ceramide/nmol lipid-Pi and are the mean þ the stan-
dard deviation of triplicate samples.
Fig. 1. Inhibition of TNFK-induced ceramide accumulation and cell death by FB1. A: Inhibition of TNFK-induced ceramide accumulation in
MCF7 cells pre-treated with FB1. MCF7 cells were treated in duplicate with TNFK with (closed circles and bars) or without (open circles and
bars) FB1 (100 WM). Ceramide levels were normalized to lipid phosphate and are presented as percentage of similarly treated cells, but in the
absence of TNFK treatment. B: Inhibition of TNFK-induced ceramide accumulation in L929 cells pre-treated with FB1. L929 cells were seeded
and treated as in (A). TNFK (open squares and bars), TNFK and FB1 (closed squares and bars). C: De novo ceramide synthesis by TNFK
and its inhibition by FB1 in MCF7 cells. MCF7 cells were labeled with [3H]palmitate as described in Section 2. Cells were treated with vehicle
(clear bar), TNFK (stippled bar), or the combination of TNFK and FB1 50 WM (brick bar). D: Inhibition of TNFK-induced cell death in
MCF7 cells pre-treated with FB1. MCF7 cells were treated as in (A) and trypan blue-positive cells were counted and are presented as a percent
of total cells counted. E: Inhibition of TNFK-induced cell death in L929 cells pre-treated with FB1. L929 cells were seeded at a density of
5U103 cells/well of a 96-well plate rested for 24 h and treated in triplicate with vehicle, TNFK, with or without the indicated concentrations of
FB1. Cleavage of WST1 is presented as percent of vehicle treated cells. Data represent at least three experiments and bars indicate S.E.M.
*Represents statistically signi¢cant di¡erences from corresponding TNFK-treated control.
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2.3. GSH measurement
Cells were seeded at 1U106 cells/ml in a 100-mm Petri dish, rested
overnight, and then treated accordingly. At the desired time points,
cells were harvested by trypsinization, washed twice with ice-cold
phosphate-bu¡ered saline, then lysed with 150 Wl of cold water. Pro-
teins were precipitated with 2% 5-sulfosalicylic acid and were sepa-
rated from the supernatant by centrifugation. GSH content in the
supernatant was measured using the Gri⁄th modi¢cation of Tietze’s
enzymatic procedure as described [6].
2.4. Sphingomyelinase activity assay
N-SMase was partially puri¢ed as described previously [5]. Activity
of sphingomyelinases was assayed by a mixed micelle assay as de-
scribed [6] using [14C]sphingomyelin as a substrate.
2.5. Statistical analysis
Statistically signi¢cant di¡erences were determined by using one-
way analysis of variance followed by Bonferroni’s post-hoc test. A
P value of less than 0.05 was considered signi¢cant. Unless otherwise
indicated, data is represented as mean þ S.E.M. based on at least three
independent experiments.
3. Results
3.1. TNFK induces de novo ceramide synthesis
Our previous studies suggested that N-SMase contributed
only part of the ceramide response to TNFK. We therefore
decided to investigate the role of de novo ceramide synthesis
in TNFK-induced ceramide accumulation and cell death. We
utilized two cell lines that have been used extensively in ex-
ploring the death-inducing e¡ects of TNFK : the MCF7 breast
carcinoma epithelial cell line and the L929 murine ¢brosarco-
ma cell line. In both cell lines, treatment with TNFK results in
gradual accumulation of cellular ceramide followed by cell
death (Fig. 1). We utilized the mycotoxin FB1 which is pro-
duced by some strains of Fusarium moniliforme. FB1 is a
structural sphingolipid analog which blocks the acylation
step in ceramide synthesis carried by ceramide synthase by
competing with sphinganine, sphingosine, and possibly also
the fatty acyl CoA [19]. In vitro, FB1 inhibits ceramide syn-
thase with an apparent Ki of 0.05^0.1 WM, but higher concen-
trations (10^30 WM) are required for inhibition of de novo
synthesis in cells. FB1 signi¢cantly inhibited the accumulation
of ceramide following TNFK over control cells treated with
FB1 alone (Fig. 1A,B). Notably, the degree of inhibition of
ceramide accumulation in the L929 cell line was compara-
tively less, indicating that de novo ceramide synthesis may
contribute a smaller fraction of the total ceramide in this
cell line. De novo ceramide synthesis in response to TNFK
was veri¢ed by showing [3H]palmitate incorporation in newly
synthesized ceramide following TNFK treatment of MCF7
cells and its inhibition by FB1 (Fig. 1C).
We next evaluated the e¡ects of FB1 on TNFK-induced cell
death. Cells were treated with TNFK in the presence or ab-
sence of FB1 and then evaluated by an inverted microscope at
14 and 24 h. In the presence of FB1, 80% of MCF7 cells and
50% of L929 cells remained attached to the plate and exhib-
ited normal morphology and spread, whereas in the absence
of FB1 more than 90% of cells had detached by 24 h in both
cell lines. When dead cells were quanti¢ed by trypan blue
uptake, it was found that FB1 provided signi¢cant protection
from the cytotoxic e¡ects of TNFK lasting until 48 h follow-
ing treatment (Fig. 1D). By 72 h, little protection from cell
death was evident in MCF7 cells treated with FB1. Similar,
but less dramatic results were observed in L929 cells (Fig. 1E).
Thus, in the TNFK-stimulated pathway of cell death, de novo
ceramide synthesis appears to be necessary for at least part of
ceramide accumulation and subsequent cell death.
Previously, it was suggested that TNFK-induced ceramide
accumulation and subsequent cell death were mediated by the
activation of N-SMase. Because of these considerations, we
evaluated the e¡ects of FB1 on the activity of partially puri-
¢ed N-SMase. Incubation of N-SMase with a range of con-
centrations of FB1 from 0.1 nM to 100 WM did not a¡ect its
activity (data not shown). In other studies, FB1 did not a¡ect
the activity of A-SMase either (data not shown).
TNFK treatment of MCF7 cells results in the loss of cellu-
lar GSH, which releases the inhibition of N-SMase and leads
to generation of ceramide from sphingomyelin hydrolysis [5].
Therefore, we examined whether FB1 indirectly a¡ects
N-SMase activity by modulating cellular GSH levels. We
Fig. 2. Inhibition of TNFK-induced ceramide accumulation and cell death by GSH. A,B: Inhibition of the early TNFK-induced ceramide re-
sponse in MCF7 or L929 cells by GSH. MCF7 (A) or L929 (B) cells were prepared as in Fig. 1A and pre-treated for 1 h with GSH prior to
treatment with TNFK. Data represent at least three experiments and bars indicate S.E.M. *Represents statistically signi¢cant di¡erences from
corresponding TNFK treated control in A,B.
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found that treatment of MCF7 cells with TNFK caused a
drop in GSH levels, as normalized to cellular protein, to
55%, 38%, and 21% of control at 1, 14, and 18 h, respectively.
Pre-treatment of MCF7 cells with FB1 did not interfere with
the drop of GSH induced by TNFK (data not shown). Similar
results were observed in L929 cells where pre-treatment of
cells with GSH attenuated the GSH drop from 19% of control
to 58%, whereas pre-treatment with FB1 had no e¡ect. These
results suggest that FB1 does not interfere with the N-SMase
pathway of ceramide generation either directly or indirectly,
and that the FB1 inhibition of de novo synthesis of ceramide
is independent of regulation of sphingomyelinases.
In order to determine that the e¡ects of FB1 were due to
inhibition of ceramide generation, we treated cells with cell-
permeable synthetic C2-ceramide (N-acetyl sphingosine) in the
presence of TNFK and FB1. We found that at 24 h, TNFK
caused 27% cell death which was reduced to 11% by FB1. C2-
ceramide at concentrations of 10, 20, and 40 WM could over-
come the inhibition of FB1 and induce cell death at 20, 39,
and 78%, respectively. This suggested that the e¡ects of FB1
were speci¢c to the interruption of the ceramide signal.
3.2. GSH regulates ceramide accumulation at
the early time points
Next, we examined the relationship of inhibition of de novo
synthesis to the inhibition of the GSH-regulated N-SMase
pathway. First, the e¡ects of modulation of GSH on
TNFK-induced ceramide accumulation were examined in
both cell lines. GSH pre-treatment resulted in inhibition of
the early accumulation of ceramide in both cell lines that
occurred up until 14 h, but it failed to inhibit the late accu-
mulation of ceramide (Fig. 2A,B). As compared to untreated
control, cell viability assessed by cleavage of WST-1 at 24 h
improved in MCF7 cells from 31% after treatment with
TNFK alone to 70% with GSH pre-treatment and 52% with
FB1 pre-treatment. In L929 cells, the GSH-induced improve-
ment in cell viability was more pronounced (TNFK 18%,
TNFK and GSH 85%, TNFK and FB1 46%). These results
con¢rm and extend previous ¢ndings that GSH depletion may
contribute to ceramide accumulation and subsequent cell
death in response to TNFK. However, it appears that the
extent of this contribution may vary between cell lines.
3.3. Independent pathways of ceramide accumulation
These ¢ndings led us to suspect the presence of two inde-
pendent pathways of ceramide generation in response to
TNFK treatment in the two cell lines examined. We examined
whether it was possible to completely block ceramide gener-
ation by blocking both pathways and whether this would
provide better protection from the cytotoxic e¡ects of
TNFK. Indeed, the combination of FB1 and GSH pre-treat-
ment of MCF7 cells almost completely abolished ceramide
accumulation at both early and late time points up to 24 h
following treatment (Fig. 3A). Subsequently, ceramide levels
started to increase as the e¡ects of the inhibitors were lost.
This combination of inhibitors delayed cell death more e¡ec-
tively than either GSH or FB1 alone (Fig. 3B). At later time
points, the rising levels of ceramide correlated with a decrease
in cell viability (data not shown). Similar results were ob-
tained in L929 cells (Fig. 3C,D). Moreover, the number of
L929 cells dying by apoptosis as determined by morphologic
criteria in response to TNFK was lower when cells were co-
treated with GSH, FB1 or the combination of GSH and FB1
(Fig. 3E,F). Therefore, although the individual contribution
of either pathway of ceramide generation may vary with cell
type, they appear to play a complementary role. The simulta-
neous inhibition of both pathways provides a similar degree of
inhibition of ceramide accumulation and cell death when both
cell lines are compared.
4. Discussion
Our ¢ndings suggest that, in response to TNFK treatment,
at least two independent pathways of ceramide generation
become activated. The GSH-dependent pathway appears to
be responsible for the earlier ceramide response and probably
involves activation of N-SMase. Our results also suggest that
other functions of GSH, such as its antioxidant properties,
may contribute to its death-inhibiting activity as evidenced
by the discrepancy between its ability to inhibit TNFK-in-
duced death and ceramide accumulation (Fig. 2). More de¢n-
itive proof of the role of N-SMase requires additional speci¢c
pharmacological inhibitors of the enzyme that currently do
not exist.
The second pathway involves ceramide synthase, which
from this study appears to be responsible for the slow but
sustained generation of ceramide occurring several hours fol-
lowing receptor ligation. Both pathways appear to contribute
independently to the induction of cell death since inhibition of
either one will partially improve cell viability. Moreover, the
contribution of the two pathways to the accumulated ceram-
ide pool may di¡er depending on the cell type involved. This
is evident by the di¡erent, but complementary e¡ects of FB1
and GSH in the two cell lines used in this study.
Several e¡ector molecules in TNFK-induced apoptosis have
been described, and their relationship to ceramide has been
examined. Receptor-activated caspases appear to be at the
apex of a signaling cascade that results in downstream events
that include the accumulation of ceramide. Inhibition of these
apical caspases by speci¢c peptide inhibitors, expression of the
viral protein CrmA, or overexpression of Bcl-xL prevents cer-
amide accumulation (both early and late) and apoptosis
Fig. 3. Inhibition of TNFK-induced ceramide accumulation and cell death by combined use of GSH and FB1. A: Inhibition of ceramide accu-
mulation in MCF7 cells. Cells were prepared as in Fig. 1A and pre-treated with GSH and FB1 (100 WM) for 1 h before treatment with TNFK.
B: Inhibition of cell death in MCF7 cells. MCF7 cells were seeded at 5U103 cells/well in a 96-well plate in triplicates and treated with the indi-
cated concentrations of GSH, FB1, or TNFK. Viability was measured by WST1 cleavage at 24 h. A representative experiment is shown. C: In-
hibition of ceramide accumulation in L929 cells (as in Fig. 3A). D: Inhibition of cell death in L929 cells in response to TNFK. L929 cells were
seeded at 5U104 cells/well in a 24-well plate and rested overnight prior to treatment with the indicated concentrations of TNFK, GSH, and
FB1. Viability at 24 h was assessed by trypan blue uptake. E: Inhibition of TNFK-induced apoptosis in L929 cells. L929 cells were seeded and
treated with TNFK with or without GSH or FB1 as indicated for 24 h. Apoptotic cells were counted after staining with Hoechst dye and are
represented as a percentage of total cells. Floating cells were not included as they were removed by washing. F: Apoptosis in response to vari-
ous treatments. L929 cells were treated as in (E) and representative ¢elds were photographed. Arrowheads indicate apoptotic cells.
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[17,20]. Ceramide has been shown to activate the downstream
caspases responsible for cleavage of ‘death’ substrates and
these e¡ects can be blocked by overexpression of Bcl-2. Im-
portantly, Bcl-2 blocks ceramide-induced activation of cas-
pases and cell death without interfering with ceramide accu-
mulation in response to TNFK or other stimuli [17,20^22].
Additionally, a role for ROI in the signaling of TNFK-in-
duced cell death has been proposed, but remains controversial
[7,23]. Ceramide has been shown to either induce the forma-
tion of ROI or to be generated in response to treatments that
speci¢cally increase the production of ROI [24,25]. Interest-
ingly, GSH is the major intracellular antioxidant responsible
for reducing ROI. Its added role in regulating N-SMase raises
the possibility that it functionally regulates these two path-
ways.
Our ¢ndings are compatible with those of a recent study
[26] that showed partial inhibition of cell death and ceramide
accumulation by FB1 in bovine cerebral endothelial cells
stimulated by a combination of TNFK and cycloheximide.
These studies underscore the importance of ceramide accumu-
lation in propagating the cell death signal in response to
TNFK and speci¢cally highlight the role for de novo ceramide
synthesis in this process. Further studies are needed to deter-
mine the roles of the di¡erent enzymes involved in ceramide
accumulation and their regulation as they may provide key
targets for speci¢c regulation of cell death.
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